微博
加入微博一起分享新鲜事
登录
|
注册
140
Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China https://journal.hep.com.cn/ip/EN/10.1016/j.ipha.2023.05.001
请登录并选择要私信的好友
300
Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China https://journal.hep.com.cn/ip/EN/10.1016/j.ipha.2023.05.001
赞一下这个内容
公开
分享
获取分享按钮
正在发布微博，请稍候